Právní předpis byl sestaven k datu 30.01.2026.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
XXXXXXXX XXXXX
xx xxx 11. prosince 2024,
xxxxxx xx mění xxxxxxxx xxxxx č. 463/2013 Xx., o xxxxxxxxx xxxxxxxxxx xxxxx, ve xxxxx pozdějších xxxxxxxx
&xxxx;
Xxxxx xxxxxxxx xxxxx §44c xxxx. 1 x 2 xxxxxx č. 167/1998 Xx., x xxxxxxxxxx xxxxxxx a x změně xxxxxxxxx xxxxxxx xxxxxx, xx xxxxx zákona x. 273/2013 Xx. x xxxxxx x. 366/2021 Xx.:
Xx. X
Xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx návykových xxxxx, xx xxxxx xxxxxxxx xxxxx x. 243/2015 Sb., xxxxxxxx xxxxx x. 46/2017 Xx., nařízení xxxxx x. 30/2018 Sb., xxxxxxxx vlády č. 242/2018 Xx., nařízení xxxxx x. 184/2021 Xx., xxxxxxxx xxxxx x. 159/2022 Xx., xxxxxxxx xxxxx x. 228/2023 Sb., xxxxxxxx xxxxx x. 52/2024 Xx. x xxxxxxxx xxxxx x. 176/2024 Xx., xx xxxx xxxxx:
1. V xxxxxxx xxxxxxx x. 1 xx xxx řádek, xx kterém xx xx sloupci x xxxxxx „Xxxxxxxxxxx xxxxxxxxxx xxxxx (INN) x xxxxxx xxxxxx“ xxxxxxx xxxxx „Thebakon“, xxxxxx xxxx xxxxx, ve xxxxxx xx ve xxxxxxx x xxxxxx „Xxxxxxxxxxx nechráněný xxxxx (XXX) x xxxxxx xxxxxx“ uvedeno xxxxx „Xxxxxxxxxxxx“, xx sloupci x xxxxxx „Chemický xxxxx xxxxx XXXXX“ xx xxxxxxx slovo „xxxxxx 4-(X-(2-xxxxxxxxxxxxx)xxxxxx)-1-(2-xxxxxxx-2-xxxxxxx)xxxxxxxxx-4-xxxxxxxxxx“ x xx xxxxxxx x xxxxxx „Xxxxxxxx“ xxxx xxxxxxx xxxxx „A-3080, Xxxxxxx“.
2. Xxxxxxx č. 3 zní:
„Příloha č. 3
Xxxxxx x. 3 xxxxxxxx xxxxx
|
Xxxxxxxxxxx nechráněný xxxxx (XXX) x&xxxx;xxxxxx xxxxxx / xxxxxx xxxxx |
Xxxxx mezinárodní xxxxxxxxxx xxxxx xxxx xxxxx xxxxxx název |
Chemický název xxxxx XXXXX |
Xxxxxxxx |
|
Xxxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)-xxxxxxxx |
XXX 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- cinnamylpiperazine; |
1-[4-(3-fenylprop-2-en-1-yl)piperazin-1-yl]butan-1-on |
|
|
AP-238 |
1-[2,6-dimethyl-4-(3-fenylprop-2-enyl)piperazin-1-yl]propan-1-on |
||
|
Benzodioxolfentanyl |
BZD-F; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx XxX |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X 4793x; X 47931X |
4-xxxx-X-(2-(xxxxxxxxxxxxx) xxxxxxxxxx) xxxxxxxx |
|
|
Xxxxxxx |
Xxxxxxxxx |
3-{1-[1-(4-xxxxxxxxx)xxxxx]xxxxxxxxx-4-xx}-1X-xxxxxxxxxxxx-2-xx |
|
|
Xxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxx-xX-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4-Xx-xXX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxx-X; CP-F |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]cyklopentankarboxamid |
|
|
Cyklopropylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]cyklopropankarboxamid |
||
|
Desmethylmoramid |
R530 |
4-(4-morfolinyl)-2,2-difenyl-1-(1-pyrrolidinyl)-1-butanon |
|
|
Desomorfin |
4,5α-epoxy-17-methylmorfinan-3-ol |
||
|
Despropionyl-2-fluor xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx fentanyl |
N-(4-fluorfenyl)-1-(2-fenylethyl)piperidin-4-amin |
||
|
Dipyanon |
4,4-difenyl-6-(pyrrolidin-1-yl)heptan-3-on |
||
|
Etazen |
etodesnitazene |
2-[2-[(4-ethoxyfenyl)methyl]benzimidazol-1-yl]-N,N-diethylethanamin |
|
|
Ethylenoxynitazen |
2-{2-[(2,3-dihydro-1-benzofuran-5-yl)methyl]-5-nitro-1H-benzimidazol-1-yl}-N,N- xxxxxxxxxxxx-1-xxxx |
||
|
Xxxxxxxxxx |
5-xxxxxx xxxxxxxxxxxxx; 5-xxxxxx xxxxxxxxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxxx-1X-xxxxxxxxxxxx-1-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
|
|
Xxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-1-(2-xxxxxxxxxx-1-xxxxxxx)-1X-xxxxxxxxxxxxx |
||
|
Xxxxxxx |
(5X,6X,7X,14X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx-6,14-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxx butanamid xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Xxxxxxxxxxxxxxxxxxxxx |
β'-xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-x]-3-xxxxxxxxxxxxxxx |
xxxxxxxxxxxxxxxxxxxxxx |
|
Xxxxxxxxxx |
X,X-xxxxxxx-2-{2-[(4-xxxxxxxxxx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}xxxxxxxxx |
||
|
2’-Xxxxx-2-xxxxx-3-xxxxxxxxxxxxxx |
X-(1-(2-xxxxxxxxxxxxx)-3-xxxxxxxxxxxxxxx-4-xx)-X-(2-xxxxxxxxxx)xxxxxxxxxxx |
||
|
4-Xxxxx-xxxxxxxxxxxxx |
4X-XX |
X-(4-xxxxxxxxxx)-X-[(1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx)]xxxxxxxxx |
|
|
4-Xxxxx-xxxxxxxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxxxx- fentanyl |
N-(4-fluorfenyl)-N-(1-benzylpiperidin-4-yl)-cyklopropankarboxamid |
|
|
2-Fluorfentanyl |
Ortofluorfentanyl |
N-(2-fluorfenyl)-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
2-FF, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, x-XX |
|
4-Xxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxx; 4X-xxxxxxxxxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxxxx-4-xx)xxxxx-2-xxxxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4X-1XX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
3-XxxxxxxxxxxxxxxxxXxxxxxxxx |
xxxxx-xxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx XX-17 |
X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxx-xxxxx-2-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
XX-X; 2-furanoylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-yl]-furan-2-karboxamid |
|
|
(iso)Butyryl-F-fentanyl X-xxxxxx xxxxxx |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-(4-xxxxxxxxxx)xxxxxxxxx |
||
|
Xxxxxx |
(5X,6X)-4,5-xxxxx-17-xxxxxxxxxxxx-7-xx-3,6-xxxx-xxxxxxxx |
||
|
4-xxxxxxxxxxxxxxxxxxxx |
4-XX-XX; x-xxxxxxxxxxxxxx xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx amin |
||
|
Karbonyl-bromadol |
(4-bromfenyl)-(1-(dimethylamino)-4-hydroxy-4-fenethylcyklohexyl)methanon |
||
|
Ketobemidon |
1-[4-(3-hydroxy fenyl)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X xxxxxxxx xxxxxx xxx léčebné xxxxxxx xxxxxxx x xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; XXX-47; XXX-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxx[x][1,3]xxxxxx-5-xxxxxxxxxx |
|
|
α-Xxxxxxxxxxxxxx xxxxxxxxx xxxxxx |
XX; X-X |
2-xxxxxx-X-xxxxx-X-[1-(1-xxxxxxxxxxx-2-xx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
3 -MethyIkrotonyIfentanyl |
β'-methyIkrotonyIfentanyl |
N-fenyl-A-[1-(2-fenylethyl)-piperidin-4-yl]-3-methylbut-2-enamid |
|
|
Metodesnitazen |
N,N-diethyl-2-[2-[(4-methoxyfenyl)methyl]benzimidazol-1-yl]ethanamin |
||
|
Metonitazen |
N,N-diethyl-2-[2-[(4-methoxyfenyl)methyl]-5-nitrobenzimidazol-1-yl]ethanamin |
||
|
Metonitazepin |
2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol |
||
|
MT-45 |
1-cyklohexyl-4-(1,2-difenylethyl)piperazin |
||
|
N-desethyletonitazen |
2-[2-[(4-ethoxyfenyl)methyl]-5-nitro-benzimidazol-1-yl]-N-ethyl-ethanamin |
||
|
N-desethylisotonitazen |
N-ethyl-2-[2-[(4-isopropoxyfenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamin |
||
|
N-methyl X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-xxxxxxxxxxx-1-xxxxxxxxxxxxx-3-xx-1-xxxxxxxxxx |
||
|
X-XXXX; xxxxxxxxxxxxxxxxxxxxxxxx |
3-(4-xxxxxx-1-xxxxxxxxxxxxxxx-4-xx)xxxxx xxxxxx |
||
|
XXxxxxxxxx |
X-3217 |
X-(2-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxxxxx, XXX, 127C49 |
1-(4,4-di(thiofen-2-yl)but-3-en-2-yl)piperidin |
|
|
Protonitazen |
N,N-diethyl-5-nitro-2-[(4-propoxyfenyl)methyl]-1-H-benzimidazol-1-ethanamin |
||
|
Protonitazepin |
5-nitro-2-[(4-propoxyphenyl)methyl]-1-(2-pyrrolidin-1-ylethyl)benzimidazole |
||
|
Pryskyřice x&xxxx;xxxxxx |
|||
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXX-X |
X-(1-xxxxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX-xxxxxxxx; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- karboxamid |
|
|
Thiofenfentanyl |
2-thiofuranyl xxxxxxxx |
X-(1-xxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
4-(Xxxxxxxxxxxxxx) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] xxxxxxxxxxxxxx |
||
|
X-51754 |
2-(3,4-xxxxxxxxxxxx)-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
XxxxxxXxxxxxxxx |
XXX, VF |
A-fenyl-N-[1-(2-fenylethyl)-4-piperidyl]pentanamid; xxxxxxxx xxxxxxxxxx xxxxxx |
Xxxxxx xxxx omamných xxxxx xxxxxxxxx x této xxxxxxx xx xxxxx xxxxxxxxx, xxx xxxx xxxx xxxxx existovat.“.
3. X xxxxxxx xxxxxxx x. 6 xx xxx xxxxx, ve xxxxxx xx xx xxxxxxx x názvem „Xxxxxxxxxxx xxxxxxxxxx název (XXX) x xxxxxx xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxxx“, xxxxxx nový xxxxx, xx kterém xx xx xxxxxxx x názvem „Xxxxxxxxxxx xxxxxxxxxx název (INN) x xxxxxx xxxxxx“ xxxxxxx slovo „Xxxxxxxxxxxxxxxx“, xx xxxxxxx s xxxxxx „Xxxxx xxxxxxxxxxx xxxxxxxxxx název nebo xxxxx obecný xxxxx“ xx xxxxxx xxxx „XXX“, xx xxxxxxx x xxxxxx „Xxxxxxxx xxxxx podle XXXXX“ xx xxxxxxx xxxxx „xxxxxx-2-xx“ x xx xxxxxxx x názvem „Xxxxxxxx“ je uvedeno xxxxx „gamma-butyrolactone“.
Čl. XX
Xxxxxxxxx xxxxxxx
Xxxx xxxxxxxx xxxx xxxxxxxx x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (EU) 2015/1535 xx dne 9. xxxx 2015 x xxxxxxx xxx xxxxxxxxxxx xxxxxxxxx x xxxxxxx technických xxxxxxxx x předpisů pro xxxxxx xxxxxxxxxx xxxxxxxxxxx.
Čl. XXX
Xxxxxxxx
Xxxx nařízení xxxxxx účinnosti xxxx 1. xxxxx 2025, x výjimkou xxxxxxxxxx čl. I bodu 3, xxxxx xxxxxx účinnosti xxxx 1. dubna 2025.
&xxxx;
Xxxxxxxx vlády:
prof. PhDr. Xxxxx, Xx.X., XX.X., x. r.
Místopředseda xxxxx x ministr xxxxxxxxxxxxx:
xxxx. XXXx. Válek, XXx., XXX, EBIR, x. x.
Informace
Právní xxxxxxx č. 419/2024 Xx. xxxxx xxxxxxxxx xxxx 1.1.2025, x výjimkou xxxxxxxxxx čl. I bodu 3, xxxxx nabývá účinnosti 1.4.2025.
Xxxxx jednotlivých právních xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx předpisu.